バイオマーカー臨床フェーズアウトソーシングサービスの世界市場レポート 2025年

バイオマーカー臨床フェーズアウトソーシングサービス市場規模は、今後数年間で飛躍的な成長が見込まれます。2029年にはCAGR22.7％で270億9,000万米ドルに成長します。この予測期間の成長は、臨床試験の様々な段階におけるバイオマーカーの利用が増加していること、臨床試験におけるバイオマーカーの利用が拡大し続けていること、精密医薬品に対する需要の高まり、コンパニオン診断の採用が増加していること、個別化医療に対する需要が高まっていることなどに起因しています。予測期間における主な動向としては、臨床試験におけるパラメータの高度化、診断に焦点を当てた臨床フェーズ、バイオマーカー技術の急速な進歩、政府のイニシアティブと資金の増加、技術の進歩などが挙げられます。

臨床試験の増加が予想されることから、バイオマーカー臨床フェーズアウトソーシングサービス市場の今後の成長が見込まれます。臨床試験には、新しい治療、介入、診断方法の安全性と有効性を評価するために、ヒトを対象として実施される調査研究が含まれます。このような臨床試験の急増は、医学研究の進歩、慢性疾患の蔓延、政府や民間からの資金提供の増加、革新的な治療法や治療法に対する需要の高まりによって促進されています。アウトソーシング・プロバイダーは多くの場合、バイオマーカーの発見、検証、分析に関する専門的な知識と専門性を有しており、臨床試験中に収集されるバイオマーカーデータの質と信頼性を高めることができます。例えば、米国国立医学図書館が2023年5月に発表したデータによると、登録された臨床試験は2022年の39万9,499件から、全米50州と221カ国で43万7,533件に増加しています。さらに、140,492試験（31％）が米国だけで登録されたのに対し、241,498試験（53％）が米国以外で記録されたことが示されました。したがって、臨床試験の増加はバイオマーカー臨床フェーズアウトソーシングサービス市場の成長を促進すると予想されます。

バイオマーカー臨床フェーズアウトソーシングサービス市場の主要企業は、競争上の優位性を獲得するため、ハイスループットなフローサイトメトリーやELISpot試験の進歩に注力しています。これらの技術はバイオマーカー分析に利用され、免疫反応や細胞マーカーを迅速かつ正確に評価することができます。例えば、米国を拠点とするバイオテクノロジー・アウトソーシング・サービス会社であるセレリオン社は、2022年11月にサービス・ポートフォリオを拡大し、GLP/GCPに準拠した分子生物学および細胞生物学試験を包含するようになりました。この戦略的拡大は、初期臨床研究から承認申請まで、医薬品開発プロセス全体を通じて顧客をサポートするセレリオンの能力を強化することを目的としています。薬物動態学的（PK）、薬力学的（PD）、バイオマーカー解析など、GLP/GCPに準拠した分子生物学的・細胞生物学的試験を追加することで、セレリオンはより包括的なサービスを提供し、顧客が規制基準を満たす高品質なデータを作成できるよう支援し、新薬開発を迅速化することができます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界バイオマーカー臨床フェーズアウトソーシングサービス PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のバイオマーカー臨床フェーズアウトソーシングサービス市場：成長率分析
• 世界のバイオマーカー臨床フェーズアウトソーシングサービス市場の実績：規模と成長, 2019-2024
• 世界のバイオマーカー臨床フェーズアウトソーシングサービス市場の予測：規模と成長, 2024-2029, 2034F
• 世界バイオマーカー臨床フェーズアウトソーシングサービス総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のバイオマーカー臨床フェーズアウトソーシングサービス市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 代替エンドポイント
• 予測バイオマーカー
• 予後バイオマーカー
• 安全性バイオマーカー
• その他のバイオマーカーの種類
• 世界のバイオマーカー臨床フェーズアウトソーシングサービス市場：サービスタイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• バイオマーカー検証
• バイオマーカー検査サービス
• バイオマーカーサンプル分析
• 世界のバイオマーカー臨床フェーズアウトソーシングサービス市場治療領域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍学
• 神経学
• 心臓病学
• 自己免疫疾患
• その他の治療領域
• 世界のバイオマーカー臨床フェーズアウトソーシングサービス市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 製薬会社
• バイオテクノロジー企業
• 学術調査機関
• 世界のバイオマーカー臨床フェーズアウトソーシングサービス市場代替エンドポイントのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍マーカーに基づくエンドポイント
• イメージングベースのエンドポイント
• 遺伝子またはゲノムマーカー
• 世界のバイオマーカー臨床フェーズアウトソーシングサービス市場予測バイオマーカーの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 遺伝的予測バイオマーカー
• タンパク質予測バイオマーカー
• メタボロミクス予測バイオマーカー
• 世界のバイオマーカー臨床フェーズアウトソーシングサービス市場予後バイオマーカーの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• がん予後バイオマーカー
• 心血管予後バイオマーカー
• 神経学的予後バイオマーカー
• 世界のバイオマーカー臨床フェーズアウトソーシングサービス市場安全性バイオマーカーの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 毒性バイオマーカー
• 薬物有害反応バイオマーカー
• 薬物相互作用バイオマーカー
• 世界のバイオマーカー臨床フェーズアウトソーシングサービス市場、その他のバイオマーカータイプのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 炎症バイオマーカー
• 感染症バイオマーカー
• 自己免疫疾患バイオマーカー

第7章 地域別・国別分析

• 世界のバイオマーカー臨床フェーズアウトソーシングサービス市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のバイオマーカー臨床フェーズアウトソーシングサービス市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• バイオマーカー臨床フェーズアウトソーシングサービス市場：競合情勢
• バイオマーカー臨床フェーズアウトソーシングサービス市場：企業プロファイル
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Labcorp Drug Development Inc. Overview, Products and Services, Strategy and Financial Analysis
  • ICON plc Overview, Products and Services, Strategy and Financial Analysis
  • Eurofins Scientific SE Overview, Products and Services, Strategy and Financial Analysis
  • WuXi AppTec Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Syneos Health Inc.
• Intertek Group plc
• Charles River Laboratories International Inc.
• Parexel International Corporation
• QIAGEN N.V.
• Medpace Inc.
• Bioclinica Inc.
• Evotec SE
• GenScript Biotech Corporation
• Precision for Medicine Inc.
• BioAgilytix Labs LLC
• Celerion Inc.
• Frontage Laboratories Inc.
• SomaLogic Inc.
• Selvita S.A.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• バイオマーカー臨床フェーズアウトソーシングサービス市場2029：新たな機会を提供する国
• バイオマーカー臨床フェーズアウトソーシングサービス市場2029：新たな機会を提供するセグメント
• バイオマーカー臨床フェーズアウトソーシングサービス市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Biomarker clinical phase outsourcing services involve contracting specialized firms or organizations to handle various aspects of clinical trials related to biomarkers. Biomarkers are measurable indicators of biological states or conditions, commonly utilized in medical research and clinical trials to evaluate the effectiveness or safety of drugs or treatments.

The primary types of biomarker clinical phase outsourcing services include surrogate endpoints, predictive biomarkers, prognostic biomarkers, safety biomarkers, and others. Surrogate endpoints serve as biomarkers intended to substitute for a clinical endpoint. Outsourcing services utilize surrogate endpoints to streamline clinical trials by providing early indications of efficacy, reducing trial duration, and potentially accelerating regulatory approvals. Service types such as biomarker validation, biomarker testing services, and biomarker sample analysis cater to therapeutic areas including oncology, neurology, cardiology, autoimmune diseases, and others. The end users typically include pharmaceutical companies, biotechnology companies, as well as academic and research institutions.

The biomarker clinical phase outsourcing services market research report is one of a series of new reports from The Business Research Company that provides biomarker clinical phase outsourcing services market statistics, including biomarker clinical phase outsourcing services industry global market size, regional shares, competitors with an biomarker clinical phase outsourcing services market share, detailed biomarker clinical phase outsourcing services market segments, market trends and opportunities, and any further data you may need to thrive in the biomarker clinical phase outsourcing services industry. This biomarker clinical phase outsourcing services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The biomarker clinical phase outsourcing services market size has grown exponentially in recent years. It will grow from $9.71 billion in 2024 to $11.94 billion in 2025 at a compound annual growth rate (CAGR) of 23.0%. The growth in the historic period can be attributed to rising government initiatives and funding, increasing diagnostic applications of biomarkers, a rise in R&D funding from the government, rapid advancements in technologies such as genomics, proteomics, and imaging, and the increasing demand for cancer biomarkers.

The biomarker clinical phase outsourcing services market size is expected to see exponential growth in the next few years. It will grow to $27.09 billion in 2029 at a compound annual growth rate (CAGR) of 22.7%. The growth in the forecast period can be attributed to the increasing use of biomarkers in the various phases of clinical trials, the use of biomarkers in clinical trials continues to expand, as does the growing demand for precision medicines, the rising adoption of companion diagnostics, and the and the increasing demand for personalized medicine. Major trends in the forecast period include advanced parameters in the trials, diagnostic-focused clinical phases, rapid advancements in biomarker technology, rising government initiatives and funding, and advancements in technology.

The anticipated increase in clinical trials is set to drive the growth of the biomarker clinical phase outsourcing services market in the future. Clinical trials involve research studies conducted with human participants to assess the safety and effectiveness of new medical treatments, interventions, or diagnostic methods. This surge in clinical trials is facilitated by advancements in medical research, the growing prevalence of chronic diseases, augmented funding from governmental and private sources, and the rising demand for innovative treatments and therapies. Outsourcing providers often possess specialized knowledge and expertise in biomarker discovery, validation, and analysis, which can enhance the quality and reliability of biomarker data collected during trials. For example, data from the United States National Library of Medicine in May 2023 revealed an increase in registered clinical trials from 399,499 in 2022 to 437,533 across all 50 states and 221 countries. Additionally, the report indicated that 140,492 studies (31%) were registered in the United States alone, while 241,498 studies (53%) were recorded in non-U.S. locations. Therefore, the rise in clinical trials is expected to propel the growth of the biomarker clinical phase outsourcing services market.

Key players in the biomarker clinical phase outsourcing services market are concentrating on advancements in high-throughput flow cytometry and ELISpot testing to gain a competitive advantage. These technologies are utilized for biomarker analysis, providing rapid and precise assessment of immune responses and cellular markers. For instance, in November 2022, Celerion Inc., a U.S.-based biotechnology outsourcing services company, broadened its service portfolio to encompass GLP/GCP-compliant molecular and cell biology testing. This strategic expansion aims to bolster Celerion's capabilities in supporting clients throughout the drug development process, from early clinical research to regulatory submissions. By adding GLP/GCP-compliant molecular and cell biology tests, such as pharmacokinetic (PK), pharmacodynamic (PD), and biomarker analysis, Celerion can offer a more comprehensive range of services to assist clients in generating high-quality data meeting regulatory standards, thereby expediting the development of new medicines.

In March 2023, SSI Strategy, a US-based life sciences consulting firm, partnered with Koneksa, a US-based health technology company specializing in digital biomarkers and clinical research. This collaboration aims to enhance patient monitoring and streamline research processes, enabling pharmaceutical and biotech companies to gain deeper insights and accelerate the development of new therapies. The partnership focuses on advancing the use of real-world and remote monitoring technologies to support more efficient and patient-centered clinical studies.

Major companies operating in the biomarker clinical phase outsourcing services market are Thermo Fisher Scientific Inc., Labcorp Drug Development Inc., ICON plc, Eurofins Scientific SE, WuXi AppTec Co. Ltd., Syneos Health Inc., Intertek Group plc, Charles River Laboratories International Inc., Parexel International Corporation, QIAGEN N.V., Medpace Inc., Bioclinica Inc., Evotec SE, GenScript Biotech Corporation, Precision for Medicine Inc., BioAgilytix Labs LLC, Celerion Inc., Frontage Laboratories Inc., SomaLogic Inc., Selvita S.A., BioIVT LLC, Discovery Life Sciences LLC, Metabolon Inc., Caprion Proteomics Inc., Canopy Biosciences LLC

North America was the largest region in the biomarker clinical phase outsourcing services market in 2024. The regions covered in the biomarker clinical phase outsourcing services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the biomarker clinical phase outsourcing services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The biomarker clinical phase outsourcing services market includes revenues earned by entities by consulting services, diagnostic tests, clinical trial design, and biomarker sample analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biomarker Clinical Phase Outsourcing Services Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on biomarker clinical phase outsourcing services market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biomarker clinical phase outsourcing services ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biomarker clinical phase outsourcing services market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Surrogate Endpoints; Predictive Biomarker; Prognostic Biomarker; Safety Biomarker; Other Biomarker Types
• 2) By Service Type: Biomarker Validation; Biomarker Testing Services; Biomarker Sample Analysis
• 3) By Therapeutic Area: Oncology; Neurology; Cardiology; Autoimmune Diseases; Other Therapeutic Areas
• 4) By End-User: Pharmaceutical Companies; Biotechnology Companies; Academic And Research Institutions
• Subsegments:
• 1) By Surrogate Endpoints: Tumor Marker-Based Endpoints; Imaging-Based Endpoints; Genetic or Genomic Markers
• 2) By Predictive Biomarker: Genetic Predictive Biomarkers; Protein Predictive Biomarkers; Metabolomic Predictive Biomarkers
• 3) By Prognostic Biomarker: Cancer Prognostic Biomarkers; Cardiovascular Prognostic Biomarkers; Neurological Prognostic Biomarkers
• 4) By Safety Biomarker: Toxicity Biomarkers; Adverse Drug Reaction Biomarkers; Drug Interaction Biomarkers
• 5) By Other Biomarker Types: Inflammation Biomarkers; Infectious Disease Biomarkers; Autoimmune Disease Biomarkers
• Companies Mentioned: Thermo Fisher Scientific Inc.; Labcorp Drug Development Inc.; ICON plc; Eurofins Scientific SE; WuXi AppTec Co. Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Biomarker Clinical Phase Outsourcing Services Market Characteristics

3. Biomarker Clinical Phase Outsourcing Services Market Trends And Strategies

4. Biomarker Clinical Phase Outsourcing Services Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Biomarker Clinical Phase Outsourcing Services Growth Analysis And Strategic Analysis Framework

• 5.1. Global Biomarker Clinical Phase Outsourcing Services PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Biomarker Clinical Phase Outsourcing Services Market Growth Rate Analysis
• 5.4. Global Biomarker Clinical Phase Outsourcing Services Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Biomarker Clinical Phase Outsourcing Services Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Biomarker Clinical Phase Outsourcing Services Total Addressable Market (TAM)

6. Biomarker Clinical Phase Outsourcing Services Market Segmentation

• 6.1. Global Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surrogate Endpoints
• Predictive Biomarker
• Prognostic Biomarker
• Safety Biomarker
• Other Biomarker Types
• 6.2. Global Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biomarker Validation
• Biomarker Testing Services
• Biomarker Sample Analysis
• 6.3. Global Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Neurology
• Cardiology
• Autoimmune Diseases
• Other Therapeutic Areas
• 6.4. Global Biomarker Clinical Phase Outsourcing Services Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmaceutical Companies
• Biotechnology Companies
• Academic And Research Institutions
• 6.5. Global Biomarker Clinical Phase Outsourcing Services Market, Sub-Segmentation Of Surrogate Endpoints, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tumor Marker-Based Endpoints
• Imaging-Based Endpoints
• Genetic Or Genomic Markers
• 6.6. Global Biomarker Clinical Phase Outsourcing Services Market, Sub-Segmentation Of Predictive Biomarker, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Genetic Predictive Biomarkers
• Protein Predictive Biomarkers
• Metabolomic Predictive Biomarkers
• 6.7. Global Biomarker Clinical Phase Outsourcing Services Market, Sub-Segmentation Of Prognostic Biomarker, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cancer Prognostic Biomarkers
• Cardiovascular Prognostic Biomarkers
• Neurological Prognostic Biomarkers
• 6.8. Global Biomarker Clinical Phase Outsourcing Services Market, Sub-Segmentation Of Safety Biomarker, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Toxicity Biomarkers
• Adverse Drug Reaction Biomarkers
• Drug Interaction Biomarkers
• 6.9. Global Biomarker Clinical Phase Outsourcing Services Market, Sub-Segmentation Of Other Biomarker Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inflammation Biomarkers
• Infectious Disease Biomarkers
• Autoimmune Disease Biomarkers

7. Biomarker Clinical Phase Outsourcing Services Market Regional And Country Analysis

• 7.1. Global Biomarker Clinical Phase Outsourcing Services Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Biomarker Clinical Phase Outsourcing Services Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Biomarker Clinical Phase Outsourcing Services Market

• 8.1. Asia-Pacific Biomarker Clinical Phase Outsourcing Services Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Biomarker Clinical Phase Outsourcing Services Market

• 9.1. China Biomarker Clinical Phase Outsourcing Services Market Overview
• 9.2. China Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Biomarker Clinical Phase Outsourcing Services Market

• 10.1. India Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Biomarker Clinical Phase Outsourcing Services Market

• 11.1. Japan Biomarker Clinical Phase Outsourcing Services Market Overview
• 11.2. Japan Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Biomarker Clinical Phase Outsourcing Services Market

• 12.1. Australia Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Biomarker Clinical Phase Outsourcing Services Market

• 13.1. Indonesia Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Biomarker Clinical Phase Outsourcing Services Market

• 14.1. South Korea Biomarker Clinical Phase Outsourcing Services Market Overview
• 14.2. South Korea Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Biomarker Clinical Phase Outsourcing Services Market

• 15.1. Western Europe Biomarker Clinical Phase Outsourcing Services Market Overview
• 15.2. Western Europe Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Biomarker Clinical Phase Outsourcing Services Market

• 16.1. UK Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Biomarker Clinical Phase Outsourcing Services Market

• 17.1. Germany Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Biomarker Clinical Phase Outsourcing Services Market

• 18.1. France Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Biomarker Clinical Phase Outsourcing Services Market

• 19.1. Italy Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Biomarker Clinical Phase Outsourcing Services Market

• 20.1. Spain Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Biomarker Clinical Phase Outsourcing Services Market

• 21.1. Eastern Europe Biomarker Clinical Phase Outsourcing Services Market Overview
• 21.2. Eastern Europe Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Biomarker Clinical Phase Outsourcing Services Market

• 22.1. Russia Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Biomarker Clinical Phase Outsourcing Services Market

• 23.1. North America Biomarker Clinical Phase Outsourcing Services Market Overview
• 23.2. North America Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Biomarker Clinical Phase Outsourcing Services Market

• 24.1. USA Biomarker Clinical Phase Outsourcing Services Market Overview
• 24.2. USA Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Biomarker Clinical Phase Outsourcing Services Market

• 25.1. Canada Biomarker Clinical Phase Outsourcing Services Market Overview
• 25.2. Canada Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Biomarker Clinical Phase Outsourcing Services Market

• 26.1. South America Biomarker Clinical Phase Outsourcing Services Market Overview
• 26.2. South America Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Biomarker Clinical Phase Outsourcing Services Market

• 27.1. Brazil Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Biomarker Clinical Phase Outsourcing Services Market

• 28.1. Middle East Biomarker Clinical Phase Outsourcing Services Market Overview
• 28.2. Middle East Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Biomarker Clinical Phase Outsourcing Services Market

• 29.1. Africa Biomarker Clinical Phase Outsourcing Services Market Overview
• 29.2. Africa Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Biomarker Clinical Phase Outsourcing Services Market Competitive Landscape And Company Profiles

• 30.1. Biomarker Clinical Phase Outsourcing Services Market Competitive Landscape
• 30.2. Biomarker Clinical Phase Outsourcing Services Market Company Profiles
  • 30.2.1. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Labcorp Drug Development Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. ICON plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Eurofins Scientific SE Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. WuXi AppTec Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Biomarker Clinical Phase Outsourcing Services Market Other Major And Innovative Companies

• 31.1. Syneos Health Inc.
• 31.2. Intertek Group plc
• 31.3. Charles River Laboratories International Inc.
• 31.4. Parexel International Corporation
• 31.5. QIAGEN N.V.
• 31.6. Medpace Inc.
• 31.7. Bioclinica Inc.
• 31.8. Evotec SE
• 31.9. GenScript Biotech Corporation
• 31.10. Precision for Medicine Inc.
• 31.11. BioAgilytix Labs LLC
• 31.12. Celerion Inc.
• 31.13. Frontage Laboratories Inc.
• 31.14. SomaLogic Inc.
• 31.15. Selvita S.A.

32. Global Biomarker Clinical Phase Outsourcing Services Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Biomarker Clinical Phase Outsourcing Services Market

34. Recent Developments In The Biomarker Clinical Phase Outsourcing Services Market

35. Biomarker Clinical Phase Outsourcing Services Market High Potential Countries, Segments and Strategies

• 35.1 Biomarker Clinical Phase Outsourcing Services Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Biomarker Clinical Phase Outsourcing Services Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Biomarker Clinical Phase Outsourcing Services Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer